Table 2.
Univariate and multivariate Cox proportional hazards regression (final model) for all-cause mortality
| Univariate |
Multivariate |
|||
|---|---|---|---|---|
| HR [95% CI] | P-value | HR [95% CI] | P-value | |
| Age (years) | 1.058 [1.046–1.071] | <0.001 | 1.04 [1.03–1.06] | <0.001 |
| Sex category (male) | 1.302 [0.960–1.766] | 0.090 | 1.15 [0.84–1.58] | 0.536 |
| Body mass index (kg/m2) | 0.977 [0.951–1.003] | 0.082 | ||
| NYHA functional class | 1.587 [1.385–1.819] | <0.001 | ||
| Primary prophylactic indication | 1.444 [1.150–1.815] | 0.002 | ||
| CRT-D | 1.515 [1.212–1.893] | <0.001 | ||
| Ischaemic cardiomyopathy | 1.501 [1.166–1.932] | 0.002 | ||
| LVEF (%) | 0.972 [0.962–0.983] | <0.001 | 0.98 [0.97–1.00] | 0.025 |
| Heart rate (b.p.m.) | 1.002 [0.998–1.005] | 0.336 | ||
| QRS duration (ms) | 1.007 [1.004–1.011] | <0.001 | ||
| QT interval (ms) | 1.003 [1.000–1.005] | 0.027 | ||
| eGFR (mL/min/1.73 m2) | 0.979 [0.974–0.984] | <0.001 | 0.99 [0.99–1.00] | 0.009 |
| Medication | ||||
| ACE inhibitors/ARB | 0.997 [0.716–1.388] | 0.986 | ||
| β-Blocker | 0.923 [0.651–1.309] | 0.654 | ||
| Digitalis | 1.507 [1.197–1.898] | <0.001 | ||
| Diuretics | 2.872 [2.058–4.008] | <0.001 | 1.81 [1.29–2.54] | 0.002 |
| MRA | 1.012 [0.805–1.273] | 0.918 | ||
| Aspirin | 0.996 [0.792–1.251] | 0.971 | 0.73 [0.58–0.93] | 0.029 |
| Coumadin | 1.305 [1.025–1.661] | 0.031 | ||
| Amiodarone | 1.308 [1.016–1.683] | 0.037 | ||
| Hypertension | 1.268 [0.940–1.712] | 0.120 | ||
| Diabetes | 1.587 [1.259–2.001] | <0.001 | ||
| History of atrial fibrillation | 1.546 [1.240–1.928] | <0.001 | ||
| Peripheral arterial disease | 2.874 [2.149–3.843] | <0.001 | 2.21 [1.62–3.00] | <0.001 |
| COPD | 1.982 [1.520–2.584] | <0.001 | 1.48 [1.13–1.94] | 0.029 |
AAD, antiarrhythmic drug; AF, atrial fibrillation; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; aspirin, acetylsalicylic acid; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CRT-D, cardiac resynchronization therapy with defibrillator; eGFR, estimated glomerular filtration rate; HR, hazard ratio; LV, left ventricular; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association.